Yamo Pharma’s L1-79 Enters Phase II Trial, May Become First FDA-Approved Autism Treatment

Yamo Pharma announced that its drug candidate L1-79 has entered Phase II clinical trials for autism treatment. If successful, it could become the first FDA-approved medication for autism.